AVX 13616

AVX 13616 shows the potent in vivo antibacterial activity of Avexa?s lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens. IC50 value: 2-4 ug/ml (MICs) Target: antibacterial agent AVX13616 was as active as mupirocin in a nasal decolonization model but required only a single application. AVX13616 and other compounds showed broad spectrum antibacterial activity against a range of isolates with MICs of 2-4 micrograms per millilitre against S. aureus, coagulase negative staphylococci, enterococci, MRSA, VISA and VRSA. The compounds are being developed for topical indications and/or wound infection/catheter-related infections. A single application of 5% (w/w) AVX13616 (approximately equimolar to 2% mupirocin) was as effective as 2% mupirocin administered twice a day for five days in nasal decolonisation of MRSA in mice.

900814-48-4

C50H73Cl2N7O7

955.08

0.98

Cl.Cl.CC(C)CCOC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCCCN)NC(=O)COc1ccc2ccccc2c1-c1c(OCCC(C)C)ccc2ccccc12